Home World News EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide World News EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 332 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... January 31, 2022 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 How I Took Charge of My Cancer Care and Found a... August 30, 2022 Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... March 22, 2019 Load more HOT NEWS As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... Catch-Up HPV Testing May Help Prevent Cervical Cancer in Some Over... FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση
